| scholarly article | Q13442814 |
| P2093 | author name string | Laakso M | |
| Tanner M | |||
| Isola J | |||
| P2860 | cites work | Cytogenetic analysis using quantitative, high-sensitivity, fluorescence hybridization | Q29616823 |
| Chromogenic in situ hybridization: a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples | Q30959521 | ||
| Her2 amplification: correlation of chromogenic in situ hybridization with immunohistochemistry and fluorescence in situ hybridization | Q46408235 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 3-9 | |
| P577 | publication date | 2006-09-01 | |
| P1433 | published in | Journal of Pathology | Q400296 |
| P1476 | title | Dual-colour chromogenic in situ hybridization for testing of HER-2 oncogene amplification in archival breast tumours | |
| P478 | volume | 210 |
| Q38612634 | Advantages and disadvantages of technologies for HER2 testing in breast cancer specimens |
| Q33629909 | Automated brightfield break-apart in situ hybridization (ba-ISH) application: ALK and MALT1 genes as models |
| Q38089259 | Biomarkers in Barrett's oesophagus and oesophageal adenocarcinoma |
| Q35984470 | Chromogenic in situ hybridisation (CISH) should be an accepted method in the routine diagnostic evaluation of HER2 status in breast cancer |
| Q26865068 | Chromogenic in situ hybridization compared with other approaches to evaluate HER2/neu status in breast carcinomas |
| Q34658220 | Combined fluorescent-chromogenic in situ hybridization for identification and laser microdissection of interphase chromosomes. |
| Q34204064 | Determination of HER-2 status on FNAC material from breast carcinomas usingin situhybridization with dual chromogen visualization with silver enhancement (dual SISH) |
| Q33794421 | Determination of HER2 amplification in primary breast cancer using dual-colour chromogenic in situ hybridization is comparable to fluorescence in situ hybridization: a European multicentre study involving 168 specimens |
| Q28731283 | Development of Multigene Expression Signature Maps at the Protein Level from Digitized Immunohistochemistry Slides |
| Q33378811 | Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybrid |
| Q53433727 | Discordant Human Epidermal Growth Factor Receptor 2 and Hormone Receptor Status in Primary and Metastatic Breast Cancer and Response to Trastuzumab |
| Q83403908 | Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer |
| Q50992951 | Dual‐colour chromogenic in‐situ hybridization is a potential alternative to fluorescence in‐situ hybridization in HER2 testing |
| Q37206247 | EGFR/HER2 in breast cancer: a biological approach for molecular diagnosis and therapy |
| Q33302191 | Epidermal growth factor receptor (EGFR) gene copy number detection in non-small-cell lung cancer; a comparison of fluorescence in situ hybridization and chromogenic in situ hybridization. |
| Q51128557 | ErbB2 diagnostics in breast cancer--an update |
| Q38089837 | Evaluation of HER2 in breast cancer: reality and expectations. |
| Q38427746 | Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays |
| Q34102078 | HER-2 oncogene amplification assessment in invasive breast cancer by dual-color in situ hybridization (dc-CISH): a comparative study with fluorescent in situ hybridization (FISH) |
| Q38314355 | HER2 assessment by silver in situ hybridization: where are we now? |
| Q35034555 | Immunohistochemical and molecular analyses of HER2 status in breast cancers are highly concordant and complementary approaches |
| Q38394606 | Instant-quality fluorescence in-situ hybridization as a new tool for HER2 testing in breast cancer: a comparative study |
| Q38019558 | Lysine methylation and the regulation of p53 |
| Q34064466 | Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma |
| Q40748887 | Silver-EnhancedIn SituHybridization as an Alternative to FluorescenceIn SituHybridization for Assaying HER2 Amplification in Clinical Breast Cancer |
| Q34363400 | The epidermal growth factor receptor family in breast cancer |
Search more.